Cell death, Immunity and Therapeutic Innovation - Lab members

 Lab members

  • Angelo PACI (PU-PH)
  • Sophie BROUTIN (PH)
  • Sofia RIVIERA (PH)
  • Awatef ALLOUCH (Post-doc)
  • Julia DELAHOUSSE (Post-doc)
  • Constance LAMY (Doc)
  • Déborah LECUYER (Doc)
  • Ali MOSTEFA-KARA (Doc)
  • Zeinaf MURADOVA (Doc)
  • Désirée TANNOUS (Doc)
  • Aurélia DEVA-NATHAN (Doc)
  • Emie GUTIERREZ-MATEYRON (Doc)

Cell death, Immunity and Therapeutic Innovation - Publications

Major publications

1. Allouch A, Paoletti A, Wu Q, Subra F, Di Pimio C, Cereseto A, Martins I, Voisin L, Dakhli H, Law F, Nardacci R, Saidi H, David A, Solary E, Deutsch E Modjtahedi N, Ojcius DM, Pancino G, Saez-Cirion A, Piacentini M, Gougeon ML, Kroemer G and Perfettini JL. Microtubule-associated SUGT1 protein dictates retroviral trafficking and susceptibility to HIV-1 infection. Cell Death Diff. (2020). doi:10.1038/s41418-020-0573-5.

Cell death, Immunity and Therapeutic Innovation

Cell death, Immunity and Therapeutic Innovation

This group belongs to the UMR 1030 - Molecular radiotherapy and therapeutic innovations

Research topics

With the ambition of optimizing the efficacy of anticancer treatments (in particular radiotherapy), we are developing a research program that aims at identifying and characterizing the mechanisms of anticancer response at genetic, metabolic as well as immunological levels.

Pediatric Precision Medicine and Experimental Therapeutics - Publications

Major publications

  1. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Handgretinger R, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy M, Cohn S, Pathiraja K, Diede S, Ebbinghaus S, Pinto N. Phase 1/2 KEYNOTE-051 study of pembrolizumab in pediatric patients with advanced melanoma or a PD-L1+ advanced, relapsed or refractory solid tumor or lymphoma. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. PMID:31812554

Pediatric Precision Medicine and Experimental Therapeutics

Pediatric Precision Medicine and Experimental Therapeutics

This group belongs to the UMR 1015 "Tumour Immunology and anti-cancer immunotherapy".

The aim of our group is to develop new innovative therapies for children with advanced cancers through our clinical precision cancer medicine trials, with one group focusing on osteosarcoma classification and development of new innovative adapted therapies in children, adolescent and young adults.

Metabolic plasticity in health and disease - Equipe

Lab members

  • Nazanine Modjtahedi, DR2, CNRS, team leader
  • Lluis M Mir, DRCE, CNRS
  • Catherine Brenner, DR2, CNRS
  • Franck M André, CRCN, CNRS
  • Giorgia Urbinati, CRCN, CNRS
  • Jean-Remi Bertrand, IR, INSERM
  • Alain Deroussent, IR, CNRS
  • Céline Gracia, IE, CNRS
  • Dawei Liu, Post-doc, INCA/CNRS
  • Camille Reinhardt, Post-doc, INCA/CNRS
  • Thai -Hoa Chung, Doc, Université Paris-Saclay
  • Amina Ghorbel, Doc, Université Paris-Saclay
  • Kenza Nedara, Doc, Université Paris-Saclay

Metabolic plasticity in health and disease - Publications

Major publications

  • Reinhardt C, Arena G, Nedara K, Edwards R, Brenner C, Tokatlidis K, Modjtahedi N. AIF meets the CHCHD4/Mia40-dependnet mitochondrial import pathway. Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165746. doi: 10.1016/j.bbadis.2020.165746.
  • Pervaiz S, Bellot G, Lemoine A, and Brenner C. Redox Signaling in the pathogenesis of human disease and the regulatory role of autophagy. Int Rev Cell Mol Biol. 2020, in press.

Chromatin remodeling, DNA repair and epigenetics - Lab members

Lab members

  • Roman Chabanon, post-doctorant
  • Thomas Eychenne, post-doctorant
  • Daphné Morel, Doctorante
  • Clémence Hénon, Doctorante,
  • Carine Ngo, Doctorante,
  • Asuka Kawai-Kawachi, ESMO Fellow
  • Marlène Garrido, Ingénieure
  • Nicolas Dorvault, Technicien
  • Léo Colmet-Daage, bioinformaticien

 

Chromatin remodeling, DNA repair and epigenetics - Publications

Major publications

  1. Epigenetic drugs in solid tumours: lessons learned and future promises? Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Nature Reviews Clinical Oncology 2019 Sep 30. doi: 10.1038/s41571-019-0267-4 [Epub ahead of print]
  2. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Chabanon RM, Morel D, Postel-Vinay S. Semin Cancer Biol. 2019 Sep 27. [Epub ahead of print]

Pages